Sign In
Buy AKTX
$14.99
+0.355 (+2.43%)
At Close: Jun 03, 2026
NEW YORK and LONDON, Aug. 18, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases
Akari Therapeutics, Plc Announces ADS Ratio Change
08:00am, Tuesday, 15'th Aug 2023
NEW YORK and LONDON, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases
Akari Therapeutics Announces the Appointment of Beth-Anne Lang as Senior Vice President, Regulatory Affairs
08:00am, Wednesday, 02'nd Aug 2023
NEW YORK and LONDON, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases
Best Penny Stocks To Buy? 6 To Watch Before Next Week
11:59am, Friday, 28'th Jul 2023
Penny stocks hold a distinctive charm for many investors. Amidst fluctuating market trends and the occasional downturn, there's often a group of these low-cost stocks surging in value.
Penny Stocks To Buy? 3 To Watch While The Stock Market Is Down
05:34pm, Thursday, 27'th Jul 2023
There's something special about penny stocks. Even when the stock market is down, like it is today, you're likely to find at least a handful exploding higher.
Akari Therapeutics to Present at Biotech Showcase™ 2023
08:00am, Wednesday, 04'th Jan 2023
NEW YORK and LONDON, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases
Akari Therapeutics (AKTX) Stock: Why It 27.88%
05:58am, Tuesday, 13'th Sep 2022
The stock price of Akari Therapeutics (AKTX) fell by 27.88% in the most recent trading session. This is why.
Akari Therapeutics Presents Results from the CASCADE and CORONET Studies in COVID-19 at the American Thoracic Society (ATS) 2022 Annual Meeting
08:05pm, Thursday, 19'th May 2022 GlobeNewswire Inc.
NEW YORK and LONDON, May 19, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company focused on developing advanced therapies for autoimmune and inflammat
NEW YORK and LONDON, May 11, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company focused on developing advanced therapies for autoimmune and inflammat
NEW YORK and LONDON, May 11, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company focused on developing advanced therapies for autoimmune and inflammator
Akari Therapeutics Announces New Data Supporting Use of Drug Candidate Votucalis Targeting Difficult to Treat Pain and Itch
12:30pm, Wednesday, 09'th Mar 2022 GlobeNewswire Inc.
Broad-acting antihistamine has potential in number of disease areas with unmet clinical need Broad-acting antihistamine has potential in number of disease areas with unmet clinical need
Akari Therapeutics Announces New Data Supporting Use of Drug Candidate Votucalis Targeting Difficult to Treat Pain and Itch
12:30pm, Wednesday, 09'th Mar 2022 GlobeNewswire
Broad-acting antihistamine has potential in number of disease areas with unmet clinical need Broad-acting antihistamine has potential in number of disease areas with unmet clinical need
Akari Therapeutics, Plc Announces $9.0 Million Registered Direct Offering
04:45pm, Tuesday, 08'th Mar 2022 GlobeNewswire Inc.
NEW YORK and LONDON, March 08, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX) (“Akari” or the “Company”), a biopharmaceutical company focused on innovative therapeutics to t
Akari Therapeutics picks new CEO
12:29pm, Wednesday, 02'nd Mar 2022 Seeking Alpha
Akari Therapeutics (AKTX) appointed Rachelle Jacques as President and CEO, effective March 2022 end; she will also join the company board.Former CEO, Clive Richardson, will continue…
Akari Therapeutics Appoints Rachelle Jacques as President and Chief Executive Officer
12:00pm, Wednesday, 02'nd Mar 2022 GlobeNewswire Inc.
Industry veteran brings extensive experience in the development and commercialization of advanced biological therapies, including in the field of complement (C5) Industry veteran brings extensive e
